Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease: Potential Uses and Pitfalls

Author： Cremers Serge   Garnero Patrick  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.66, Iss.16, 2006-01, pp. : 2031-2058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents

By  

Current Pharmaceutical Analysis, Vol. 1, Iss. 3, 2005-11 ,pp. : 225-241

Bentham Science Publishers

Access to resources Recommend Favorite

Battling Bone Disease: New Drugs Strengthen the Osteoporosis Market

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 6, 2004-11 ,pp. : 3-8

Adis International

Access to resources Recommend Favorite

Urinary Bone Turnover Markers as Target Indicators for Monitoring Bisphosphonate Drug Treatment in the Management of Osteoporosis

By  

Current Drug Targets, Vol. 19, Iss. 5, 2018-03 ,pp. : 451-459

Bentham Science Publishers

Access to resources Recommend Favorite

Pegvisomant normalises markers of bone turnover in acromegaly

By  

Inpharma, Vol. 1, Iss. 1424, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Effects of Combined Treatment with Calcitriol plus Alendronate on Bone Mass and Bone Turnover in Postmenopausal Osteoporosis: Two Years of Continuous Treatment

By Frediani B.   Allegri A.   Bisogno S.   Marcolongo R.  

Clinical Drug Investigation, Vol. 15, Iss. 3, 1998-03 ,pp. : 235-244

Adis International

Access to resources Recommend Favorite